Institutional members access full text with Ovid®

Share this article on:

Impact of Varicella Vaccination on Varicella-related Hospitalizations Among American Indian/Alaska Native People

Singleton, Rosalyn J. MD, MPH*; Holman, Robert C. MS; Person, Marissa K. MSPH; Steiner, Claudia A. MD; Redd, John T. MD§; Hennessy, Thomas W. MD; Groom, Amy MPH; Holve, Stephen MD**; Seward, Jane F. MB BS, MPH††

The Pediatric Infectious Disease Journal: March 2014 - Volume 33 - Issue 3 - p 276–279
doi: 10.1097/INF.0000000000000100
Original Studies

Background: Routine childhood varicella vaccination, implemented in 1995, has resulted in significant declines in varicella-related hospitalizations in the United States. Varicella hospitalization rates among the American Indian (AI) and Alaska Native (AN) population have not been previously documented.

Methods: We selected varicella-related hospitalizations, based on a published definition, from the Indian Health Service inpatient database for AI/ANs in the Alaska, Southwest and Northern Plains regions (1995–2010) and from the Nationwide Inpatient Sample for the general US population (2007–2010). We analyzed average annual hospitalization rates prevaccine (1995–1998) and postvaccine (2007–2010) for the AI/AN population, and postvaccine for the general US population.

Results: From 1995–1998 to 2007–2010, the average annual varicella-related hospitalization rate for AI/ANs in the 3 regions decreased 95% (0.66–0.03/10,000 persons); the postvaccine rate appears lower than the general US rate (0.06, 95% confidence interval: 0.05–0.06). The rate declined in all AI/AN pediatric age groups. Infants experienced the highest prevaccine (14.07) and postvaccine (0.83) hospitalization rates. Adults experienced low rates in both periods. Varicella vaccination rates in 19- to 35-month-old AI/AN children during fiscal years 2008–2010 were 88.1–91.0%.

Conclusions: Widespread use of varicella vaccine in AI/AN children was accompanied by substantial declines in varicella-related hospitalizations consistent with high varicella vaccine effectiveness in preventing severe varicella outcomes.

From the *Alaska Native Tribal Health Consortium, Anchorage, AK; Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services (USDHHS), Atlanta, GA; Healthcare Cost and Utilization Project, Center for Delivery, Organization and Markets, Agency for Healthcare Research and Quality, USDHHS, Rockville, MD; §Indian Health Service (IHS), USDHHS, Santa Fe, NM; Arctic Investigations Program, NCEZID, CDC, USDHHS, Anchorage, AK; Immunization Services Division, CDC, USA USDHHS, Atlanta, GA; **Tuba City Regional Health Care, IHS, USDHHS, Tuba City, AZ; and ††Division of Viral Diseases, National Center for Immunization and Respiratory Disease, CDC, GA.

Accepted for publication September 19, 2013.

The authors have no funding or conflicts of interest to disclose.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (www.pidj.com).

Address for Correspondence: Rosalyn Singleton, MD; AIP-CDC, 4055 Tudor Centre Dr, Anchorage, AK 99508. E-mail: ris2@cdc.gov.

© 2014 by Lippincott Williams & Wilkins, Inc.